Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
NEW YORK, March 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Imprivata, Inc. (“Imprivata”) (NYSE:IMPR) between July 30, 2015 and November 2, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. If you purchased or otherwise acquired Imprivata securities between July 30, 2015 and November 2, 2015, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/imprivata.
The complaint alleges that during the Class Period, defendants made materially false and misleading statements and/or omitted material information concerning demand for the Company’s IT security offerings and its sales trends, thereby inflating the price of Imprivata stock. The complaint further alleges that certain Imprivata executives and insiders took advantage of the inflation by selling more than $72 million worth of personally-held Imprivata stock during this time period.
If you suffered a loss in Imprivata you have until April 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/imprivata.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
